Lindane to Stay in Market for Lice, Scabies Treatment, Says DTAB
New Delhi: Refusing to impose a complete ban, the Drugs Technical Advisory Board (DTAB) has recommended the continued marketing of Lindane, a topical medication used as a second-line treatment for scabies and lice, despite earlier prohibitions on its agricultural use by the Ministry of Agriculture.
The Board emphasized its affordability and effectiveness in treating parasitic skin conditions, while also advising the issuance of safety guidelines for its disposal and labeling.
The Drugs Technical Advisory Board (DTAB), in its 92nd meeting held on April 24, 2025, deliberated on the proposal to prohibit the manufacture, sale, and import of Lindane, a topical treatment used in dermatology for scabies and lice infestations.
According to the official minutes of the meeting, the Board was apprised of previous regulatory actions taken under the Insecticides Act. Specifically, it noted:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.